logical support. Most dissatisfaction was with lack of advice on financial aspects of care and lack of psychological counseling, with women tending to express more dissatisfaction with care. Many patients complained about the way ophthalmologists delivered bad news to them. Conclusions: This patients' perspective highlights directions for research, education, and other measures to improve the care of patients with ocular melanoma in the US and elsewhere.
Patients with Uveal Melanoma
The 180 patients with uveal melanoma (130 women, 50 men) had a median age of 58 years (range, 26-81) when they completed the questionnaire. The tumor involved choroid in 167 (92.7%) patients, ciliary body in 9 (5.0%), and iris in 4 (2.2%). The follow-up time between diagnosis and questionnaire had a median of 3.0 years (range, 0.12-24.6).
Detection
One hundred and twelve (62.6%) of 179 patients answering the questions (i.e., 179 "respondents") were initially informed of their tumor by an ophthalmologist and 55 (30.7%) by an optometrist, with 12 (6.7%) reporting another provider. Mydriasis was reported by 151 (90.4%) of 167 patients with posterior uveal melanoma, with 13 (7.8%) stating that their pupils were not dilated and 3 (1.8%) not answering. Immediate referral to an ocular oncologist was reported by 151 (87.8%) of 172 respondents.
Diagnosis
The tumor was diagnosed by an ocular oncologist in 148 (84.6%) of 175 respondents, by another ophthalmologist in 21 (12.0%), and another practitioner in 6 (3.4%). The distance traveled to this practitioner exceeded 250 miles in 33 (18.5%) patients. The time between tumor detection and diagnosis exceeded 4 weeks in 34 (19.1%) patients. Of 160 respondents, 53 (33.1%) reported that their melanoma had previously been diagnosed as a nevus. In these patients, surveillance exceeded 36 weeks in 28 (51%).
Ocular Treatment
In 174 respondents, ocular treatment was plaque brachytherapy in 136 (78.2%), proton beam radiotherapy in 17 (9.8%), enucleation in 18 (10.3%), stereotactic radiotherapy in 1 (0.6%), transpupillary thermotherapy in 1 (0.6%), and excision in 1 patient (0.6%).
Of 176 patients with a posterior uveal melanoma, 110 (62.5%) reported their tumor thickness at the time of treatment, which was categorized as ≤3.0 mm in 27 (40.6%) of these, 3.1-6.0 mm in 27 (40.6%), and >6.0 mm in 13 (18.8%). One patient mentioned receiving 3 different thickness estimates from 3 specialists.
Treatment was received within 1 week of diagnosis in 39 (22.2%) of 176 respondents, 1-2 weeks from diagnosis in 33 (18.8%) and more than 4 weeks from diagnosis in 46 (25.6%).
Receiving information on plaque brachytherapy was reported by 158 (87.8%) patients, enucleation by 102 (56.7%), proton beam radiotherapy by 48 (26.7%), and transpupillary thermotherapy by 20 (11.1%).
Eleven (6.7%) of 165 respondents reported tumor recurrence, after brachytherapy (9) , proton beam radiotherapy (1) , and enucleation (1), respectively, with the time to recurrence exceeding 3 years in 6 out of the 8 patients providing this information. Enucleation more than 3 months after primary ocular treatment was reported by 11 patients.
Prognostic Biopsy
Of 164 respondents, 102 (62.2%) reported that they had received information on biopsy. Gene expression profiling (GEP) was discussed by 38 (26.2%) patients, chromosome 3 testing by 28 (15.6%), multiplex ligationdependent probe amplification/microsatellite (MLPA/ MSA) analysis by 4 (2.2%), GNAQ/11 by 3 (1.7%), Foundation 1 testing by 2 (1.1%), and single nucleotide polymorphism (SNP) analysis by 1 (0.6%).
With regard to the test performed, in 158 respondents, GEP was mentioned by 42 (23.3%), monosomy 3 by 29 
Metastatic Disease
Metastatic disease was reported by 19 (11.2%) of 169 respondents. One (7.7%) out of 13 with a class 1A melanoma result developed metastasis, as compared to 0 of 16 patients with a class 1B melanoma and 4 of 22 (18.2%) with a class 2 melanoma.
Physician Experience and Communication
With regard to communication aids, brochures were mentioned by 84 patients (46.7%), links to online information by 22 (12.2%), printed internet material by 19 (10.6%), handwritten notes by 16 (8.9%), links to patient support groups, such as the OMF, by 12 (6.7%), copy of the medical report by 1 patient, and permission to obtain an audio-recording of the consultation by 1 patient. Sixty-five patients (36.1%) stated that no aids were provided. Sixty-four (35.5%) patients reported that they were informed of the number of patients the ocular oncologist treats annually with the proposed modality.
Psychological Support
Twenty-four (13.3%) of 169 respondents reported an offer of psychological support whereas 145 (85.8%) reported not receiving this support. Twenty-two (22.2%) out of 99 respondents reported emotional support had been provided when they received a poor prognosis. Table 1 summarizes patients' satisfaction with their experience, according to their gender. Most dissatisfaction was with financial advice and psychological counseling. Women were most dissatisfied with counseling on financial matters and metastasis prevention.
Satisfaction with Care Received

Need for More Information
Patients mostly wished for better information on paying for their care and psychological counseling ( Table 2) . Compared to men, women were more interested in the impact of their disease on activities and quality of life.
Conjunctival Melanoma
There were 4 patients with conjunctival melanoma (3 women). The tumor was detected by an optometrist in 3 patients and by an ophthalmologist in 1. Three patients were immediately referred to an ocular oncologist but 1 patient was monitored for over a year. One patient was dissatisfied with the detection process. One patient was satisfied with the information provided. The therapeutic modalities reported to have been received were topical chemotherapy (2), proton beam radiotherapy (2), cryotherapy (1), excision (1), enucleation (1), and exenteration (1). One patient experienced recurrence. One patient reported having GEP of the tumor and 1 reported MLPA/ MSA. Three wanted more information on the impact of the disease on their life. One patient received psychological support. Two patients were offered screening for metastatic disease and 2 developed metastasis.
Patients' Comments
The questionnaire gave patients the opportunity to provide comments, the most informative of which are listed in the Appendix.
Discussion
Main Findings
This study provides insights into the patient's perspective of the care currently received for ocular melanoma in the US. It complements studies published by academics, which report clinical results that indicate what care patients should receive. Deficiencies are highlighted throughout the care pathway. This study should stimulate measures to improve the patient's healthcare experience, well-being, and clinical outcomes.
Strengths and Weaknesses
The strengths of the study are the large number of patients from across the US and the inclusion of patients treated in a wide variety of units. The questionnaire was designed by patients, through the OMF, so that topics most relevant to them were investigated.
There are also weaknesses to this study. First, patients' scores do not necessarily reflect the quality of care provided, because patients may lack extensive medical knowledge. For example, some patients screened for metastasis were satisfied with liver function tests and chest radiography, which have low sensitivity and specificity [1] . Nevertheless, the data usefully indicate educational needs requiring attention.
Second, self-selection of participants biased the results. For example, our cohort with uveal melanoma comprised 130 women and 50 men, whereas this tumor is known to affect both sexes in equal numbers [2] . We remedied this by reporting experience and information needs according to gender (Table 1, 2) .
Third, the reliability of the patients' data is uncertain. For example, patients may have remembered dates and events incorrectly and may have misheard or misunderstood what they were told about tumor dimensions. 
Methodology
Only US patients were included to avoid conflicting data from other countries. It would be interesting to compare patients' experience in different countries.
We did not exclude patients with conjunctival melanoma, because their needs are as great as those with uveal melanoma and their comments equally insightful. Because the two types of melanoma differ greatly, patients with conjunctival melanoma were reported separately. The anecdotal evidence of clinical shortcomings suggests that there is scope for further studies focusing on this group of patients, but with larger numbers.
Caregivers' responses were excluded because of possible bias resulting from "second-hand" information. Comparison of patients' and caregivers' responses is planned.
Clinical Implications
Detection Some reported that their tumor was initially missed. A study of 2,384 patients with uveal melanoma in the UK found that the tumor was missed in 23% patients, who were more likely to have advanced disease when reaching an ocular oncology center and less likely to retain vision and the eye [3] . Although patients in this study expressed satisfaction with the detection process there is scope for improvement (e.g., mydriasis, examining the entire fundus and not only the "disc and macula," and checking for episcleral sentinel vessels). Diagnosis About a third of patients reported their tumor was initially diagnosed as a nevus. This raises the question as to how many patients did not benefit from color photography, autofluorescence imaging, and optic coherence tomography, possibly because these methods were not widely available when they were investigated.
Primary Ocular Treatment
The primary treatment was usually brachytherapy. Figure 1 shows great geographic variation in treatment selection, suggesting treatment tends to be selected according to what is available at the treating center rather than according to tumor features. The principle of "Informed consent" dictates that this is acceptable only if patients are counseled about the risks and benefits of all therapies and 286 not only those available at the center the patient happens to visit. Such a standard may not be met universally, as suggested by the small proportion of patients receiving information on proton beam radiotherapy.
Few patients reported tumor recurrence and/or secondary enucleation; however, the follow-up time was short, with a median of only 3 years. There is scope for further studies evaluating outcomes after treatment for ocular melanoma across the US. The IRIS Registry of the American Academy of Ophthalmology may in future be useful in this respect [4] . Approximately 90% of patients indicated they were happy with the additional information provided by tumor genetics. This is in keeping with some (but not all) previous studies [5] [6] [7] . Further studies are needed.
Screening and Treatment for Metastasis
The results of this study indicate a wide variety of screening tests for metastatic disease, including insensitive tests (e.g., liver function tests and chest radiography) as well as CT and positron-emission tomography, which expose patients to ionizing radiation [8] . The value of screening has been questioned, because treatment for metastasis only rarely prolongs life [9, 10] ; however, therapeutic methods are advancing rapidly. There is some evidence that screening may nevertheless improve patients' well-being because a normal test result provides reassurance that health is unlikely to deteriorate in the near future. In this study, patients expressed dissatisfaction with metastatic treatment, probably because of the ineffectiveness of such therapy and the high incidence of severe side effects.
Physician Experience and Communication
Most patients mentioned that they had received a communication aid about their disease. However, only a minority felt that they had received adequate information. We and others at other ocular oncology services provide patients with several communication aids (i.e., audio-recordings of the consultation, information sheets, online information, access to clinical records, telephone helpline run by specialist nurse).
Psychological Support This survey suggests a need for improvement in the way that ophthalmologists give patients bad news. There is also evidence of unmet needs for emotional support and psychological counseling from a qualified health professional. More work is needed to identify the best methods for addressing these needs.
Information Needs
This survey indicates that patients need more information on financial matters, on the likely impact of their tumor on daily life, and on how to talk to children, other relatives, friends, and colleagues about their cancer. These needs could be met by guiding patients to appropriate online information, which is more likely to be readily updated than printed brochures (e.g., American Cancer Society, https://www.cancer.org/cancer.html).
Conclusions
This study highlights limitations in several aspects of care. There is scope for guidelines similar to those published in the UK and elsewhere for uveal melanoma, retinoblastoma and other malignancies [11, 12] . On the basis of this study, we tentatively propose a short list of standards of care for patients with ocular melanoma, as a basis for discussion and refinement (Table 3 ). There is scope for minimum specifications defining the resources that should be available at US centers treating patients with ocular melanoma (e.g., training and qualifications of healthcare providers, equipment, psychological support). This survey also indicates directions for research, education, and other measures to improve the care of patients with ocular melanoma in the US and beyond.
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The authors have no conflicts of interest to disclose. to diagnose even after 6 months of bi-monthly visits. Called me a "diagnostic dilemma." Should have sent me to a specialist sooner. Consent • The main thing I wish had been done differently is that the ophthalmologist who first photographed my nevus should have told me that there was a chance, however small, that it would become a tumor, and that's why I should have it watched. Even though he told me to come back in a year, he basically told me it was nothing to worry about. So, I didn't go back for two years. • I wish I had been encouraged, given the risks, to treat the "nevus" when it was discovered rather than waiting for 5 years and then finding out it was a class two tumor. The doctors were always so worried about saving my vision. I wish they had been more concerned with saving my life. • I was led to believe I had a benign tumor. Then when definitively diagnosed, I had exactly 30 min to make critical decisions as to treatment.
Funding Sources
• It seems each doctor pushes their own agenda. One only does plaque and one only does laser.
• The pain upon waking up back at the hotel after enucleation was something we really weren't adequately prepared for.
• He was great as far as getting the tumor but very unconcerned with the other things that happened with the eye after the tumor was taken care [of].
• The tumor detection and diagnosis scored low because the tumor was detected 2 years prior but wasn't correctly diagnosed. When I was treated at an ocular oncology center 2 years later (Nov 2014), the care was amazing. believe that while the internet is wonderful to purchase a handbag or new golf club it is the wrong venue to seek out medical information and advice, particularly with something this serious. What I read on the internet both frightened and confused me. I wished that there was someone or some avenue to seek information and counseling. • Doctor could have had better bedside manner and spent more time with me or offered someone else qualified to answer my questions.
• The communication between the surgeon and my family physicians didn't happen until I asked for it.
• There needs to be an active network that patients sign up for so they are contacted about, for example, a clinical trial that fits their profile.
• I wish I knew more about the various modalities of treatment and given sufficient time to make decisions. • When I was first being watched ([for] the nevus) I suggested that the fear was this turning into a melanoma. I couldn't get any of my doctors to acknowledge this possibility. I think patients should be told of the risk associated with this type of nevus and given counseling/education at this point. • I know it was hard to hear and understand the full impact of the diagnosis and treatment while undergoing the actual surgery and pain management. I feel having the process re-explained, a number of times, would have been helpful for me at that time • [I] was not told of other options of treatment other than plaque nor informed of genetic testing.
• We were told to search "Google" for further information.
• My surgeon led me to believe that once my eye was enucleated, I was home free. He does no follow-up in that respect. He never told me I had a 50% chance of this [metastasis] happening. He is arrogant and only cares about the eye and nothing else.
• I was not made to understand that it was cancer we were talking about. The doctor later said he didn't want to scare me. He kept saying, "try not to worry." Then once he said "I would be worried." Also, he didn't talk about any options. Psychological Support • I had no clue that I was going to receive a devastating diagnosis.
The doctor bluntly told me I had a huge ciliary body melanoma and sent me to the waiting room by myself to wait for a referral to the ocular oncologist: no kindness, no support, no concern for what that news meant to me. • I had great care overall, but it would have even better if I could have been referred to a live or at least online support group. • I presented a very calm exterior, but I was actually horrified at the prospect of loss of my sight, eye and possibly my life. Also, facial disfigurement was a concern. I wish my doctors had acknowledged how frightening a diagnosis it is. • I wish I had been offered psychological counseling.
• My diagnosis was communicated in a very clinical manner, with very little compassion shown.
• I was abruptly told that I had a cancer in my eye, that the treatment was to take the eye out, that the doctor had room in his surgery schedule a week from Thursday, and that I was to stop by the receptionist to make the appointment. Nothing more.
• Rude, cold...uncaring doctor. Too clinical with very little support information given at the time. He delivered the news and left the room. • I was told over the phone in a rather unfeeling way.
• [Suggestions:] [information on] treatment available and genetic testing; encourage psychological counseling to help with the acceptance of our disease and someone to just listen to our fears and concerns; a place where others with our disease can get together so we don't feel isolated and can share our experiences with. • [Suggestions:] Follow-up phone calls after treatment.
• The doctor just wanted to focus on the eye with cancer not the person with the cancer! • You get a breast cancer diagnosis and immediately everyone reaches their arms out to you, making you meals, offering to help. You become part of a community. With this -there is no community unless you go online, and find groups -only to discover the various "camps" within this community are divided and competitive and care more about their own group being the "face" of ocular melanoma than they do the actual people who HAVE the cancer. • The protocol after the plaque treatment was bloodwork every 6 months and X-ray of lungs every 12 months. I believe the metastasis to the liver would have been found earlier if CT was part of the protocol every 6 months.
• I wish the MDs talked more about ways to monitor the disease, besides CT scans. For instance, doing MRIs, which expose [me to] less radiation.
• I wish my oncologist would approve/order an MRI for surveillance. I have CT of the chest, abdomen and pelvis every 6 months.
• The oncologist I was referred to for follow-up care refused to schedule MRIs -only 6-month ultrasounds since it wouldn't matter when the metastases were found. "Once you have metastasis you're dead anyway." I don't see that doctor anymore.
• Happy with screening done at time of dx but no further screening was recommended except LFT. and not caused delays in approving things.
• There should be a group to help fight insurance when insurance denies payment on treatments.... Having to deal with being screwed by insurance, even when you have it, is just as traumatic as the diagnosis, the fear and concern of leaving your family in financial ruin, etc.
• I wish I knew how to handle the finances better. I am still paying for an MRI that I had last summer at xxx. It was over $5,000. My insurance only paid a fraction of that.
• I wish that physicians would realize that even if a patient survives, their life is changed. I feel like there were so many things I wanted to do, places I wanted to visit, but the expenses (even with insurance) have made me so broke I'll never get to go there. I feel I'll spend the rest of my life working to pay for my cancer treatments. No one understands this.
• I was not offered genetic testing or counseling for either emotional or financial (problems). Note: Words inserted by the authors are enclosed in square brackets. Grammatical errors have been corrected.
